ARTICLE | Company News
Mimetogen, Allergan deal
November 9, 2015 8:00 AM UTC
Mimetogen granted Allergan exclusive, worldwide rights to develop and commercialize tavilermide ( MIM-D3) to treat dry eye diseases. Mimetogen will receive $50 million up front and is eligible to rece...